Quantum-Si, Inc. (QSI)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.77+0.66%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Broken: Primary pillar broken — Limit total cash usage to $93 million in 2026: Cash usage $98M vs $93M target.
Quantum-Si aims to reach $1 million revenue in 2026. It plans to limit operating expenses to $98 million and cash usage to $93 million. The company has shown recent earnings beats and is developing a next-gen protein sequencing platform. These targets show a path to stabilize the business.
Revenue growth is weak and expected to decline about 13%. The company is loss-making with negative cash flow and high expenses. Recent market selling pressure reflects risks in execution and capital constraints.
The market expects about -13% revenue growth and values the stock near $0.21. Our view aligns with this cautious outlook given the company's losses and limited revenue progress.
Breaks if: cash usage exceeds $93 million in FY26
The company plans to limit total cash usage to $93 million or less for the full year 2026.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. QSI is navigating a challenging environment with elevated risk while focusing on key product launches and cost management.
The market appears to have priced in a high level of fragility due to its expensive valuation, which is not fully justified given the company's current performance and risks. There is a significant expectations gap, indicating that investors may be anticipating stronger results than what the fundamentals currently support.
Management is focused on launching the Proteus platform and controlling operating expenses, which could stabilize the company's financials. However, recent changes show a decline in company quality, and the near-term risk of missing earnings remains moderate.
The thesis hinges on the successful commercial launch of the Proteus platform and the overall health of the healthcare sector. Key triggers include guidance updates from management and performance from sector leaders that could influence investor sentiment.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read on QSI. It indicates strong revenue potential for 2026 and extends the cash runway into Q4 2028. However, the delay in the Proteus platform's launch to Q2 2027 threatens growth objectives.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: operating expenses exceed $98 million in FY26
Breaks if: revenue falls below $1 million in FY26
Over the next 1 to 3 years, QSI's performance will depend on its execution of strategic priorities and external market conditions. Not investment advice.